Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Histopathologic placental findings in severe acute respiratory syndrome coronavirus 2 exposed gravida compared to unexposed controls: a single center retrospective cohort study.

Placenta·2025

Same author

Little Loopers: A Case Series of Automated Insulin Delivery Usage with Standard and Diluted Insulin in Very Young Children with Diabetes Mellitus.

Hormone research in paediatrics·2025

Same author

Building a Home for Family Medicine: Reflections on the Development of a Consultant Clinic at Mangochi District Hospital in Rural Malawi.

Family medicine·2025

Same author

Bedside Utilization of Intestinal Pathology in Preterm Infants with Surgical Necrotizing Enterocolitis.

American journal of perinatology·2024

Same author

Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory.

Diabetologia·2023

Same author

Early development of infant gut microbiota in relation to breastfeeding and human milk oligosaccharides.

Frontiers in nutrition·2023

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.

Rachel M Williams¹, Anna McDonald, Martin O'Savage

¹University of Cambridge, Department of Paediatrics, Addenbrookes Hospital, Box 116, Hills Road, Cambridge CB2 2QQ, UK.

Expert Opinion on Drug Metabolism & Toxicology

|March 28, 2008

Summary

Mecasermin rinfabate, a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and rhIGFBP-3, shows similar efficacy and side effects to rhIGF-I alone. Further pharmacokinetic data in humans is needed.

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Area of Science:

Endocrinology
Pharmacology
Biotechnology

Background:

Mecasermin rinfabate (iPLEX) combines rhIGF-I with rhIGFBP-3 to extend IGF-I half-life and potentially reduce side effects.
Administered as a daily subcutaneous injection, it has been investigated for various growth and endocrine disorders.

Purpose of the Study:

To conduct a literature review on the pharmacokinetics, safety, and clinical efficacy of Mecasermin rinfabate.
To consolidate existing research on this rhIGF-I/rhIGFBP-3 complex.

Main Methods:

A systematic literature search was performed using the NCBI PubMed portal.
Search terms included "rhIGF-I/rhIGFBP-3 complex", "iPLEX", and "Somatokine".

Main Results:

Mecasermin rinfabate has been studied in conditions like diabetes, severe insulin resistance, osteopenia, burns, and growth hormone insensitivity syndrome.
Clinical outcomes observed were comparable to those of rhIGF-I monotherapy.

Conclusions:

The biological effects of Mecasermin rinfabate are consistent with those of rhIGF-I.
Limited published data exists on its human pharmacokinetics, and its side effect profile mirrors that of rhIGF-I.